Access cutting-edge scid-x1 treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access scid-x1 specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related scid-x1 treatment provided free
This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol. Enrollment of subjects will be agreed upon by representatives of both sites. Data will be
Sponsor: David Williams
Check if you qualify for this scid-x1 clinical trial in Los Angeles, CA
If you're searching for scid-x1 treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced scid-x1 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.